Company profile for Therapix Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.With this focus, the company is currently engaged in the following drug development programs based on repurposing an FDA-approved cannabinoid (Dronabinol): THX-...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.With this focus, the company is currently engaged in the following drug development programs based on repurposing an FDA-approved cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
4 Ariel Sharon Street Hashahar Tower, 16th Floor Givatayim 5320047
Telephone
Telephone
+972–3‑6167055
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/therapix-biosciences-and-cyntar-ventures-entered-a-non-binding-letter-of-intent-for-the-distribution-of-therapea-in-canada-301201046.html

PRNEWSWIRE
05 Jan 2021

https://www.prnewswire.com/news-releases/therapix-biosciences-to-collaborate-with-the-university-of-calgary-to-further-examine-its-proprietary-drug-candidate-thx-160-for-pain-301183621.html

PRNEWSWIRE
02 Dec 2020

https://www.prnewswire.com/il/news-releases/therapix-biosciences-to-collaborate-with-the-university-of-calgary-to-further-examine-its-proprietary-drug-candidate-thx-160-for-pain-301183621.html

PRNEWSWIRE
02 Dec 2020

https://www.prnewswire.com/news-releases/therapix-biosciences-issues-ceo-letter-to-its-shareholders-301181620.html

PRNEWSWIRE
30 Nov 2020

https://www.prnewswire.com/news-releases/therapix-biosciences-announces-replacement-of-its-board-of-directors-301116296.html

PRNEWSWIRE
21 Aug 2020

https://www.prnewswire.com/news-releases/therapix-biosciences-announces-otc-pink-ticker-symbol-trpxy-and-removal-of-injunction-by-israeli-court-301090928.html

PRNEWSWIRE
09 Jul 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty